

WE ARE ENTRUSTED WITH THE MOST



WE ARE ENTRUSTED WITH THE MOST VALUABLE!

BORIMED









Joint Stock Company «Borisovskiy zavod medicinskikh preparatov» is a leading manufacturer and exporter of broadspectrum medications in the Republic of Belarus.







Company profile



Our company was founded in 1965. Today it occupies an area of over 19.13 hectares and employs 2 666 staff.

The company's annual production output exceeds 5 billion tablets, 200 million capsules, 15 million ointment tubes, 15 million tincture bottles and solutions, 300 million ampoules with solutions for injection and 40.0 million antibiotic vials.

Our industrial output at actual 2021 prices for 2021 stood at 372.4 billion rubles (\$143.5 million).

"BZMP" JSC is now a modern, dynamically developing pharmaceutical company boasting cutting edge technology, qualified personnel and high production culture.







Company product portfolio:

More than 250 names of medications

12 pharmacotherapeutic groups

About 10 new medications are launched into production annually







MAIN DOSAGE FORMS:

Powders for Solutions Tablets (including Liquid Soft dosage forms injections in for those with modified Capsules phytochemicals (ointments, gels) vials (tinctures, drops) injections release) (antiobiotics)


BZMP JSC possesses more than 300 manufacturing pharmaceutical technologies





PRODUCT PORTFOLIO STRUCTURE:









Domestic trade partners:




Domestic market sales in Belarus for 2021 год totaled:

170.4 mln. Bel. Roubles 65.7 mln. (in USD equivalent)

Growth rate, compared to 2020:

105.7%






23 % - private distribution companies 77% -state owned distribution network "Pharmatsia" RUE





Sales regions

















TOTAL FOREIGN SALES

Foreign sales in **2021** totaled to **75.6 mln**. **USD** \$







REALIZED INVESTMENT PROJECTS



Description of investment projects	Realization terms	Project value, mln. USD
Setup of aseptic antibiotic filling and packing facility	2013-2015	25.5
Reconstruction of the ampule filling facility	2015 – 2018	25.0
"Setup of production of new import- substituting solid dosage forms" (2nd phase)	2018-2021	2.4





Prospective investment projects



Description of investment projects	Realization terms	Project value, mln. USD
Setup of a new production of solid dosage forms	2021- 2029	50.0
Reconstruction of the tablet manufacturing workshop	2021-2028	25.0
Renovation of a production building on 8.3 hectares for a finished goods warehouse	2021-2024	6.4
Setup of the production of medicinal preparations	2026-2030	80.0





INVESTMENT PROJECT



"Setup of a new production of solid dosage forms"

"Project objective: setting up new production facilities (1 336 million tablets per year) to manufacture solid dosage forms in accordance with GMP standards to increase the range of import-substituting pharmaceuticals, maintain and boost the company's export potential, develop production of competitive products and create technologically advanced jobs.





PROJECT SUCCESS CRITERIA



Annual revenues after reaching the projected capacity – 145 401 thousand USD.

Dynamic payback period - 14 years

Simple payback period - 9 years 5 months



PROJECT SUCCESS CRITERIA



Net present value (NPV) at the end of the time horizon – 2 677 thousand roubles.

Internal rate of return (IRR) - 5.0%

Profitability index (PI) - 1.05

Export orientation of the project (surplus of exports over import) -56.7%



INVESTMENT COSTS & EXPENSES



Total investment expenses under the project including VAT and expenses for the increase of the net working capital during the time horizon will equal to 129 877.0 thousand rubles (53 644 thousand USD).

The capital costs in current prices, including VAT, will make 120 345.4 thousand rubles (49 707 thousand USD), including: fixed capital investments under the project totaling to 111 060 thousand rubles (45 872 thousand USD); Increase in the net working capital during the time horizon is expected to hit 9 531.6 thousand rubles (3 937 thousand USD).



Investment costs & expenses

The total capital costs in current prices, including VAT, will make 120 345.4 thousand roubles (49 707 thousand USD), including:

- ✓ **pre-investment costs** 1 676.4 thousand roubles (692 thousand USD);
- ✓ equipment 64 635.7 thousand roubles (26 697 thousand USD);
- ✓ construction and assembly works 37 082.90 thousand roubles (15 317 thousand USD);
- ✓ miscellaneous expenses 16 950.4 thousand roubles
 7 001 thousand USD.

 BORIMED ★

The design and estimate documentation provides for construction of a new 7-storey building (on an existing land plot of 0.50 ha) which will be connected to the existing workshop No. 4 by a transition gallery to allow for using the same integrated technology and methods of production of solid dosage forms.





The project provides for prospective development of the existing production facility. Implementation of the innovative project "Creation of new production of solid dosage forms" involves using innovative pharmaceutical technologies:

- ✓ **Metformin Long,** 750 mg tablets No. 30, Metformin Long, 1000 mg tablets No. 30 (oral hypoglycemic preparation);
- ✓ **Spasmaton Neo,** coated tablets no. 20 (non-steroidal anti-inflammatory and anti-rheumatic preparation).







Currently, the pharmaceutical market of the Republic of Belarus has no analogues of the innovative medicinal preparations Metformin Long 750 mg, 1000 mg prolonged release tablets and Spasmaton Neo coated tablets, planned for production at the new facilities (JSC "BZMP" is the only manufacturer in the Republic of Belarus).

- ✓ **Metformin Long** 750 mg tablets No. 30, Metformin Long 1000 mg tablets No. 30 (oral hypoglycemic preparation);
- ✓ **Spasmaton Neo,** coated tablets no. 20 (non-steroidal anti-inflammatory and anti-rheumatic preparation).











You are welcome to join a mutually beneficial cooperation!

«BZMP» JSC

Republic of Belarus, 220518

64, Chapaeva str., Borisov

Tel. (+375 177) 73 22 61

fax (+375 177) 73 24 25

E-mail: borimed@borimed.com

www.borimed.com







Thanks for attention!



+375(177) 73 22 61



www.borimed.com



